The Latest Breaking News from FDA

Here's what the pros have to say about VDPHL01.

 

The tablets were distributed nationwide in up to 1,000-count bottles

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.

On Friday, the U.S. Food and Drug Administration (FDA) approved GSK Plc’s (NYSE:GSK) Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.

Every time you see the words “FDA approved,” it’s supposed to mean safety, science, and trust. After all, the Food and Drug Administration is the final checkpoint before a product reaches your medicine cabinet, right? But history says otherwise. Over the years, some truly shocking—and sometimes disastrous—products have slipped through…

Neutrogena recalls makeup wipes after tests found harmful bacteria, urging consumers to stop use immediately.

Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average up 0.3% at 46,734.61, the SP 500 advancing nearly 0.6% to 6,738.44, and the Nasdaq climbing about 0.9% to 22,941.79.These are the top stocks that gained the attention of retail traders and investors through the day: Intel…